PMID- 21171155
OWN - NLM
STAT- MEDLINE
DCOM- 20110328
LR  - 20131121
IS  - 1552-4965 (Electronic)
IS  - 1549-3296 (Linking)
VI  - 96
IP  - 2
DP  - 2011 Feb
TI  - Mineral trioxide aggregate solution inhibits osteoclast differentiation through 
      the maintenance of osteoprotegerin expression in osteoblasts.
PG  - 358-64
LID - 10.1002/jbm.a.32990 [doi]
AB  - Mineral trioxide aggregate (MTA) is a therapeutic, endodontic repair material 
      that is reported to exhibit calcified tissue-conductive activity. The aim of this 
      study was to investigate whether MTA may prevent osteoclast differentiation in 
      vitro. MTA solution, but not other commonly used retrofilling materials, such as 
      Dycal, Super-EBA, or intermediate restorative material (IRM) solution, 
      dose-dependently inhibited osteoclastogenesis in cocultures of mouse bone marrow 
      cells (BMCs) with primary osteoblast cells (POBs) induced by 
      1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2) D(3) ]. Exogenous CaCl(2) medium 
      supplementation did not inhibit osteoclastogenesis in cocultures. Furthermore, 
      MTA solution did not affect receptor activator of NF-kappaB ligand (RANKL)-induced 
      osteoclastogenesis, suggesting that POBs are targets of MTA. MTA solution 
      suppressed the 1alpha,25(OH)(2) D(3) -induced reduction of osteoprotegerin (OPG) mRNA 
      and protein production without changing RANKL expression in POBs. Consistent with 
      this result, MTA solution did not inhibit osteoclastogenesis in cocultures of 
      BMCs and POBs from OPG-deficient mice. Therefore, the maintenance of OPG 
      expression in POBs appears to be critical for the inhibitory effect of MTA 
      solution on osteoclast differentiation.
CI  - 2010 Wiley Periodicals, Inc.
FAU - Hashiguchi, Daisuke
AU  - Hashiguchi D
AD  - Division of Molecular Signaling and Biochemistry, Department of Biosciences, 
      Kyushu Dental College, 2-6-1 Manazuru, Kokurakita-ku, Kitakyushu, Fukuoka 
      803-8580, Japan.
FAU - Fukushima, Hidefumi
AU  - Fukushima H
FAU - Nakamura, Midori
AU  - Nakamura M
FAU - Morikawa, Kazumasa
AU  - Morikawa K
FAU - Yasuda, Hisataka
AU  - Yasuda H
FAU - Udagawa, Nobuyuki
AU  - Udagawa N
FAU - Maki, Kenshi
AU  - Maki K
FAU - Jimi, Eijiro
AU  - Jimi E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101206
PL  - United States
TA  - J Biomed Mater Res A
JT  - Journal of biomedical materials research. Part A
JID - 101234237
RN  - 0 (Aluminum Compounds)
RN  - 0 (Calcium Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Osteoprotegerin)
RN  - 0 (Oxides)
RN  - 0 (RANK Ligand)
RN  - 0 (Silicates)
RN  - 0 (Solutions)
RN  - 0 (mineral trioxide aggregate)
RN  - FXC9231JVH (Calcitriol)
RN  - M4I0D6VV5M (Calcium Chloride)
SB  - IM
MH  - Aluminum Compounds/*pharmacology
MH  - Animals
MH  - Bone Marrow Cells/cytology/drug effects/metabolism
MH  - Calcitriol/pharmacology
MH  - Calcium Chloride/pharmacology
MH  - Calcium Compounds/*pharmacology
MH  - Cell Differentiation/*drug effects
MH  - Coculture Techniques
MH  - Drug Combinations
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Mice
MH  - Osteoblasts/cytology/*drug effects/*metabolism
MH  - Osteoclasts/*cytology/*drug effects/metabolism
MH  - Osteogenesis/drug effects
MH  - Osteoprotegerin/genetics/*metabolism
MH  - Oxides/*pharmacology
MH  - RANK Ligand/pharmacology
MH  - Silicates/*pharmacology
MH  - Solutions
EDAT- 2010/12/21 06:00
MHDA- 2011/03/29 06:00
CRDT- 2010/12/21 06:00
PHST- 2010/04/13 00:00 [received]
PHST- 2010/09/29 00:00 [revised]
PHST- 2010/10/05 00:00 [accepted]
PHST- 2010/12/21 06:00 [entrez]
PHST- 2010/12/21 06:00 [pubmed]
PHST- 2011/03/29 06:00 [medline]
AID - 10.1002/jbm.a.32990 [doi]
PST - ppublish
SO  - J Biomed Mater Res A. 2011 Feb;96(2):358-64. doi: 10.1002/jbm.a.32990. Epub 2010 
      Dec 6.